Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Gilead's remdesivir data 'directionally positive,' says Piper Sandler » 11:41
07/10/20
07/10
11:41
07/10/20
11:41
GILD

Gilead

$76.61 /

+1.94 (+2.60%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$76.61 /

+1.94 (+2.60%)

GILD Gilead
$76.61 /

+1.94 (+2.60%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
GILD Gilead
$76.61 /

+1.94 (+2.60%)

GILD Gilead
$76.61 /

+1.94 (+2.60%)

GILD Gilead
$76.61 /

+1.94 (+2.60%)

GILD Gilead
$76.61 /

+1.94 (+2.60%)

Hot Stocks
Cocrystal says eligible to receive up to $156M in payments, royalties from Merck » 11:28
07/10/20
07/10
11:28
07/10/20
11:28
MRK

Merck

$76.83 /

+0.125 (+0.16%)

, COCP

Cocrystal Pharma

$2.03 /

+0.2 (+10.93%)

In presentation slides,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$76.83 /

+0.125 (+0.16%)

COCP Cocrystal Pharma
$2.03 /

+0.2 (+10.93%)

MRK Merck
$76.83 /

+0.125 (+0.16%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
COCP Cocrystal Pharma
$2.03 /

+0.2 (+10.93%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 H.C. Wainwright
Cocrystal Pharma initiated with a Buy at H.C. Wainwright
06/16/20 Noble Capital
Cocrystal Pharma initiated with an Outperform at Noble Capital
MRK Merck
$76.83 /

+0.125 (+0.16%)

  • 31
    Oct
MRK Merck
$76.83 /

+0.125 (+0.16%)

MRK Merck
$76.83 /

+0.125 (+0.16%)

MRK Merck
$76.83 /

+0.125 (+0.16%)

Downgrade
BeiGene downgraded at CLSA on 'likely weak' Q2 U.S. sales from new products » 11:28
07/10/20
07/10
11:28
07/10/20
11:28
BGNE

BeiGene

$197.08 /

-3.29 (-1.64%)

CLSA downgraded BeiGene…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BGNE BeiGene
$197.08 /

-3.29 (-1.64%)

BGNE BeiGene
$197.08 /

-3.29 (-1.64%)

11:24 Today CLSA
BeiGene downgraded to Outperform from Buy at CLSA
06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
BGNE BeiGene
$197.08 /

-3.29 (-1.64%)

BGNE BeiGene
$197.08 /

-3.29 (-1.64%)

Downgrade
BeiGene downgraded to Outperform from Buy at CLSA » 11:24
07/10/20
07/10
11:24
07/10/20
11:24
BGNE

BeiGene

$198.34 /

-2.03 (-1.01%)

CLSA downgraded BeiGene…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BGNE BeiGene
$198.34 /

-2.03 (-1.01%)

BGNE BeiGene
$198.34 /

-2.03 (-1.01%)

06/03/20 Piper Sandler
BeiGene earned 'meaningful' approvals for Brukinsa in China, says Piper Sandler
03/25/20 Piper Sandler
BeiGene Abraxane issue could take months to resolve, says Piper Sandler
03/13/20 Macquarie
BeiGene upgraded to Neutral from Underperform at Macquarie
03/03/20 Maxim
BeiGene price target lowered to $190 from $210 at Maxim
BGNE BeiGene
$198.34 /

-2.03 (-1.01%)

BGNE BeiGene
$198.34 /

-2.03 (-1.01%)

Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 10:18
07/10/20
07/10
10:18
07/10/20
10:18
ABEO

Abeona Therapeutics

$3.02 /

-0.33 (-9.85%)

, AMGN

Amgen

$247.24 /

-4.025 (-1.60%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$86.61 /

-0.71 (-0.81%)

, PFE

Pfizer

$33.69 /

+0.24 (+0.72%)

, SNY

Sanofi

$50.25 /

-0.31 (-0.61%)

, VRCA

Verrica Pharmaceuticals

$9.70 /

+0.94 (+10.73%)

45th Annual Virtual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$247.24 /

-4.025 (-1.60%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.69 /

+0.24 (+0.72%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

  • 20
    Dec
AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

Options
Unusually active option classes on open July 10th » 09:40
07/10/20
07/10
09:40
07/10/20
09:40
FIT

Fitbit

$6.71 /

+ (+0.00%)

, GILD

Gilead

$74.67 /

+ (+0.00%)

, W

Wayfair

$228.88 /

+ (+0.00%)

, TSM

TSMC

$64.76 /

+ (+0.00%)

, ROKU

Roku

$149.63 /

+ (+0.00%)

, SPCE

Virgin Galactic

$19.45 /

+ (+0.00%)

, SRNE

Sorrento Therapeutics

$7.72 /

+ (+0.00%)

, AMD

AMD

$57.29 /

+ (+0.00%)

, BYND

Beyond Meat

$141.13 /

+ (+0.00%)

, LYFT

Lyft

$29.90 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Fitbit (FIT), Gilead (GILD), Wayfair (W), Taiwan Semi (TSM), Roku (ROKU), Virgin Galactic (SPCE), Sorrento Therapeutics (SRNE), Advanced Micro (AMD), Beyond Meat (BYND), and Lyft (LYFT).

ShowHide Related Items >><<
W Wayfair
$228.88 /

+ (+0.00%)

TSM TSMC
$64.76 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$7.72 /

+ (+0.00%)

SPCE Virgin Galactic
$19.45 /

+ (+0.00%)

ROKU Roku
$149.63 /

+ (+0.00%)

LYFT Lyft
$29.90 /

+ (+0.00%)

GILD Gilead
$74.67 /

+ (+0.00%)

FIT Fitbit
$6.71 /

+ (+0.00%)

BYND Beyond Meat
$141.13 /

+ (+0.00%)

AMD AMD
$57.29 /

+ (+0.00%)

FIT Fitbit
$6.71 /

+ (+0.00%)

06/19/20 Deutsche Bank
Fitbit acquisition completing remains base case at Deutsche Bank
11/27/19 Deutsche Bank
Second Fitbit suitor should limit downside if deal breaks, says Deutsche Bank
11/06/19 DA Davidson
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
11/04/19 DA Davidson
Fitbit downgraded to Neutral from Buy at DA Davidson
GILD Gilead
$74.67 /

+ (+0.00%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
W Wayfair
$228.88 /

+ (+0.00%)

07/07/20 Baird
Wayfair price target raised to $225 from $190 at Baird
07/01/20 Deutsche Bank
Farfetch price target raised to $23 from $17 at Deutsche Bank
06/26/20 SunTrust
Wayfair price target raised to $208 from $163 at SunTrust
06/26/20 Wells Fargo
Wayfair price target raised to $215 from $170 at Wells Fargo
TSM TSMC
$64.76 /

+ (+0.00%)

04/28/20
Fly Intel: Top five analyst initiations
04/28/20 Wedbush
Wedbush bullish on TSMC, initiates with an Outperform
04/27/20 Wedbush
TSMC initiated with an Outperform at Wedbush
04/17/20 Susquehanna
TSMC downgraded to Negative from Positive at Susquehanna
ROKU Roku
$149.63 /

+ (+0.00%)

06/11/20 Oppenheimer
Roku price target raised to $140 from $135 at Oppenheimer
06/04/20 Rosenblatt
Roku weakness on new TCL TVs 'well overdone,' says Rosenblatt
06/03/20 Stephens
Roku may be seeing pressure from Best Buy TCL TVs, says Stephens
06/03/20 SunTrust
New TVs at Best Buy present 'modest' new competition for Roku, says Suntrust
SPCE Virgin Galactic
$19.45 /

+ (+0.00%)

03/24/20 Morgan Stanley
Morgan Stanley upgrades Virgin Galactic to Overweight after over 70% drop
03/24/20 Morgan Stanley
Virgin Galactic upgraded to Overweight from Equal Weight at Morgan Stanley
03/03/20 Morgan Stanley
Lead up to next lunar landings can have 'powerful impact,' says Morgan Stanley
02/27/20
Fly Intel: Top five analyst downgrades
SRNE Sorrento Therapeutics
$7.72 /

+ (+0.00%)

05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
10/07/19 JMP Securities
Sorrento Therapeutics initiated with an Outperform at JMP Securities
07/23/19 H.C. Wainwright
Sorrento Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
AMD AMD
$57.29 /

+ (+0.00%)

06/19/20 Jefferies
AMD still taking share in CPU-only cloud instances, says Jefferies
06/15/20 Piper Sandler
AMD well positioned for continued market share gains, says Piper Sandler
06/15/20 Nomura Instinet
AMD on pace for 20%-30% sales growth in 2020, says Nomura Instinet
06/12/20 Rosenblatt
Rosenblatt says Jim Keller's departure from Intel a 'big deal'
BYND Beyond Meat
$141.13 /

+ (+0.00%)

06:16 Today Citi
Citi starts Beyond Meat with Sell, sees 15% share downside
05:46 Today Citi
Beyond Meat initiated with a Sell at Citi
07/09/20 Bernstein
Beyond Meat price target raised to $133 from $118 at Bernstein
06/29/20
Fly Intel: Top five analyst downgrades
LYFT Lyft
$29.90 /

+ (+0.00%)

06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
06/11/20
Fly Intel: Top five analyst initiations
06/10/20 BTIG
Lyft initiated with a Buy at BTIG
06/03/20 KeyBanc
KeyBanc sees 'some of most compelling' secular dynamics for ridesharing
W Wayfair
$228.88 /

+ (+0.00%)

TSM TSMC
$64.76 /

+ (+0.00%)

SPCE Virgin Galactic
$19.45 /

+ (+0.00%)

ROKU Roku
$149.63 /

+ (+0.00%)

LYFT Lyft
$29.90 /

+ (+0.00%)

GILD Gilead
$74.67 /

+ (+0.00%)

FIT Fitbit
$6.71 /

+ (+0.00%)

BYND Beyond Meat
$141.13 /

+ (+0.00%)

AMD AMD
$57.29 /

+ (+0.00%)

  • 03
    Jun
  • 20
    May
  • 17
    Mar
  • 01
    Aug
W Wayfair
$228.88 /

+ (+0.00%)

TSM TSMC
$64.76 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$7.72 /

+ (+0.00%)

SPCE Virgin Galactic
$19.45 /

+ (+0.00%)

ROKU Roku
$149.63 /

+ (+0.00%)

LYFT Lyft
$29.90 /

+ (+0.00%)

GILD Gilead
$74.67 /

+ (+0.00%)

FIT Fitbit
$6.71 /

+ (+0.00%)

BYND Beyond Meat
$141.13 /

+ (+0.00%)

AMD AMD
$57.29 /

+ (+0.00%)

W Wayfair
$228.88 /

+ (+0.00%)

TSM TSMC
$64.76 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$7.72 /

+ (+0.00%)

SPCE Virgin Galactic
$19.45 /

+ (+0.00%)

ROKU Roku
$149.63 /

+ (+0.00%)

LYFT Lyft
$29.90 /

+ (+0.00%)

GILD Gilead
$74.67 /

+ (+0.00%)

FIT Fitbit
$6.71 /

+ (+0.00%)

BYND Beyond Meat
$141.13 /

+ (+0.00%)

AMD AMD
$57.29 /

+ (+0.00%)

W Wayfair
$228.88 /

+ (+0.00%)

TSM TSMC
$64.76 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$7.72 /

+ (+0.00%)

SPCE Virgin Galactic
$19.45 /

+ (+0.00%)

ROKU Roku
$149.63 /

+ (+0.00%)

LYFT Lyft
$29.90 /

+ (+0.00%)

GILD Gilead
$74.67 /

+ (+0.00%)

FIT Fitbit
$6.71 /

+ (+0.00%)

BYND Beyond Meat
$141.13 /

+ (+0.00%)

AMD AMD
$57.29 /

+ (+0.00%)

On The Fly
Fly Intel: Pre-market Movers » 09:06
07/10/20
07/10
09:06
07/10/20
09:06
GILD

Gilead

$74.67 /

-0.96 (-1.27%)

, ZIOP

Ziopharm

$3.24 /

+0.04 (+1.25%)

, ALV

Autoliv

$63.32 /

-0.9 (-1.40%)

, MATX

Matson

$27.46 /

-0.69 (-2.45%)

, GBX

Greenbrier

$21.75 /

-0.895 (-3.95%)

, SLP

Simulations Plus

$63.55 /

+1.57 (+2.53%)

, BYND

Beyond Meat

$141.13 /

-3.735 (-2.58%)

, SC

Santander Consumer

$17.32 /

-1.005 (-5.48%)

, FSLY

Fastly

$102.67 /

+6.52 (+6.78%)

, RIG

Transocean

$1.90 /

-0.12 (-5.96%)

, CNTG

Centogene

$17.06 /

-2.1 (-10.96%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

CNTG Centogene
$17.06 /

-2.1 (-10.96%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

06/19/20 Jefferies
Ziopharm initiated with a Buy at Jefferies
05/11/20 H.C. Wainwright
Ziopharm price target lowered to $5.50 from $6.50 at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst initiations
03/04/20 Cantor Fitzgerald
Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald
ALV Autoliv
$63.32 /

-0.9 (-1.40%)

07/09/20 Goldman Sachs
Autoliv initiated with a Buy at Goldman Sachs
06/19/20 JPMorgan
Autoliv price target raised to $63 from $55 at JPMorgan
06/11/20 Evercore ISI
Autoliv upgraded to In Line from Underperform at Evercore ISI
05/28/20 Wolfe Research
Autoliv downgraded to Peer Perform from Outperform at Wolfe Research
MATX Matson
$27.46 /

-0.69 (-2.45%)

07:36 Today Stifel
Matson price target raised to $44 from $35 at Stifel
04/06/20 Stephens
Matson downgraded to Equal Weight from Overweight at Stephens
02/27/20 Stifel
Matson upgraded to Buy from Hold at Stifel
GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

04/28/20 Susquehanna
Greenbrier downgraded to Negative from Neutral at Susquehanna
04/08/20 KeyBanc
Greenbrier price target lowered to $30 from $38 at KeyBanc
01/14/20 Wells Fargo
Greenbrier downgraded to Underweight from Equal Weight at Wells Fargo
11/08/19 Susquehanna
Greenbrier downgraded to Neutral from Positive at Susquehanna
SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

08:31 Today Craig-Hallum
Simulations Plus price target raised to $75 from $56 at Craig-Hallum
06/08/20 Craig-Hallum
Simulations Plus price target raised to $56 from $40 at Craig-Hallum
01/06/20 Craig-Hallum
Simulations Plus initiated with a Buy at Craig-Hallum
BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

06:16 Today Citi
Citi starts Beyond Meat with Sell, sees 15% share downside
05:46 Today Citi
Beyond Meat initiated with a Sell at Citi
07/09/20 Bernstein
Beyond Meat price target raised to $133 from $118 at Bernstein
06/29/20
Fly Intel: Top five analyst downgrades
SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

06/03/20 Stephens
Stephens says Santander Consumer may benefit if Wells pulling back on auto loans
05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
03/17/20 Barclays
Santander Consumer downgraded to Underweight from Equal Weight at Barclays
01/06/20 Stephens
Stephens upgrades Santander Consumer to Equal Weight ahead of expected buybacks
FSLY Fastly
$102.67 /

+6.52 (+6.78%)

06:26 Today BofA
Fastly double-downgraded to Underperform from Buy at BofA
06:05 Today BofA
Fastly downgraded to Underperform from Buy at BofA
07/09/20 Citi
Citi recommends overweight Zoom Video, underweight Fastly pair trade
07/09/20 Citi
Citi downgraded Fastly to Sell with stock up 400% in three months
RIG Transocean
$1.90 /

-0.12 (-5.96%)

07/08/20 Morgan Stanley
Morgan Stanley downgrades Transocean to Equal Weight on offshore drilling view
07/08/20 Morgan Stanley
Transocean downgraded to Equal Weight from Overweight at Morgan Stanley
07/02/20 Evercore ISI
Transocean secures contract for 20k PSI drillship, says Evercore ISI
06/15/20
Fly Intel: Top five analyst downgrades
CNTG Centogene
$17.06 /

-2.1 (-10.96%)

04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
12/02/19 BTIG
Centogene initiated with a Buy at BTIG
ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

MATX Matson
$27.46 /

-0.69 (-2.45%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

  • 10
    Jul
  • 21
    May
  • 05
    Feb
  • 07
    Nov
  • 01
    Aug
RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GBX Greenbrier
$21.75 /

-0.895 (-3.95%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

CNTG Centogene
$17.06 /

-2.1 (-10.96%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

ALV Autoliv
$63.32 /

-0.9 (-1.40%)

ZIOP Ziopharm
$3.24 /

+0.04 (+1.25%)

SLP Simulations Plus
$63.55 /

+1.57 (+2.53%)

SC Santander Consumer
$17.32 /

-1.005 (-5.48%)

RIG Transocean
$1.90 /

-0.12 (-5.96%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

FSLY Fastly
$102.67 /

+6.52 (+6.78%)

BYND Beyond Meat
$141.13 /

-3.735 (-2.58%)

Hot Stocks
Gilead up 2% to $76.30 after remdesivir shows 62% reduction in mortality risk  08:52
07/10/20
07/10
08:52
07/10/20
08:52
GILD

Gilead

$74.67 /

-0.96 (-1.27%)

 
ShowHide Related Items >><<
GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

Hot Stocks
Gilead announces additional data on remdesivir for treatment of COVID-19 » 08:41
07/10/20
07/10
08:41
07/10/20
08:41
GILD

Gilead

$74.67 /

-0.96 (-1.27%)

Gilead Sciences announced…

Gilead Sciences announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir. Gilead said in a release, "The data are being presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference and include a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19. In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62 percent reduction in the risk of mortality compared with standard of care - an important finding that requires confirmation in prospective clinical trials. Separate subgroup analyses from the Phase 3 SIMPLE-Severe trial, including an evaluation of the safety and efficacy of remdesivir across different racial and ethnic patient subgroups treated in the United States, found that traditionally marginalized racial or ethnic groups treated with remdesivir in this study experienced similar clinical outcomes as the overall patient population in the study. Gilead is also presenting new analyses of the company's compassionate use program, which demonstrated that 83 percent of pediatric patients and 92 percent of pregnant and postpartum women with a broad spectrum of disease severity recovered by Day 28. No new safety signals were identified with remdesivir across these populations. To further the understanding of these results in individual patient cases, Gilead recently announced the initiation of a global, open-label Phase 2/3 trial to evaluate the safety, tolerability and pharmacokinetics of remdesivir in pediatric patients from birth to less than 18 years of age. Gilead is also collaborating on a study for pregnant women. Due to the current public health emergency, the FDA has issued an Emergency Use Authorization for remdesivir for the treatment of hospitalized patients with severe COVID-19. In the United States, remdesivir is an investigational drug that has not been approved by the FDA, and the safety and efficacy of remdesivir for the treatment of COVID-19 has not been established... This comparative pre-planned analysis included 312 patients treated in the Phase 3 SIMPLE-Severe study and a separate real-world retrospective cohort of 818 patients with similar baseline characteristics and disease severity who received standard of care treatment in the same time period as the SIMPLE-Severe study... The results of this comparative analysis add to the previously presented National Institute of Allergy and Infectious Disease, or NIAID, randomized, double-blind, placebo-controlled study in hospitalized patients with COVID-19, which showed that remdesivir shortened time to recovery by an average of four days as compared to placebo. In the NIAID study, patients taking remdesivir trended toward lower mortality compared with those in the placebo group, but this result did not reach statistical significance."

ShowHide Related Items >><<
GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

Conference/Events
International Aids Society to hold a virtual conference » 04:55
07/10/20
07/10
04:55
07/10/20
04:55
ABT

Abbott

$93.68 /

+1.11 (+1.20%)

, BDX

Becton Dickinson

$258.57 /

+5.92 (+2.34%)

, GILD

Gilead

$74.67 /

-0.96 (-1.27%)

, HOLX

Hologic

$57.45 /

-0.13 (-0.23%)

, MRK

Merck

$76.70 /

-1.17 (-1.50%)

, OSUR

OraSure

$13.86 /

+0.495 (+3.71%)

23rd International AIDS…

23rd International AIDS Virtual Conference: AIDS 2020 will be held on July 6-10. Webcast Link

ShowHide Related Items >><<
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

07/09/20
Fly Intel: Top five analyst upgrades
07/09/20 Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
07/09/20 Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
GILD Gilead
$74.67 /

-0.96 (-1.27%)

04:49 Today Stifel
Galapagos downgraded to Hold from Buy at Stifel
06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
HOLX Hologic
$57.45 /

-0.13 (-0.23%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$76.70 /

-1.17 (-1.50%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

  • 03
    Jun
  • 21
    May
MRK Merck
$76.70 /

-1.17 (-1.50%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

OSUR OraSure
$13.86 /

+0.495 (+3.71%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

BDX Becton Dickinson
$258.57 /

+5.92 (+2.34%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

MRK Merck
$76.70 /

-1.17 (-1.50%)

HOLX Hologic
$57.45 /

-0.13 (-0.23%)

GILD Gilead
$74.67 /

-0.96 (-1.27%)

ABT Abbott
$93.68 /

+1.11 (+1.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.